Publicaciones en las que colabora con Luis Barral (3)

2022

  1. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7

2019

  1. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats

    Biochemical Pharmacology, Vol. 170